Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Daifotis, Anastasia G."'
Autor:
Sherry, Nicole, Hagopian, William, Ludvigsson, Johnny, Jain, Sunil M, Wahlen, Jack, Ferry, Robert J, Jr, Bode, Bruce, Aronoff, Stephen, Holland, Christopher, Carlin, David, King, Karen L, Wilder, Ronald L, Pillemer, Stanley, Bonvini, Ezio, Johnson, Syd, Stein, Kathryn E, Koenig, Scott, Herold, Kevan C, Daifotis, Anastasia G
Publikováno v:
In The Lancet 2011 378(9790):487-497
Autor:
Thiede, Mark A., Daifotis, Anastasia G., Weir, Eleanor C., Brines, Michael L., Burtis, William J., Ikeda, Kyoji, Dreyer, Barbara E., Garfield, Robert E., Broadus, Arthur E.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1990 Sep 01. 87(18), 6969-6973.
Externí odkaz:
https://www.jstor.org/stable/2355144
Autor:
Luckey, Marjorie M, Gilchrist, Nigel, Bone, Henry G, Davie, Michael W, de Villiers, Tobias J, Wu, Mei, Daifotis, Anastasia G, Santora, Arthur C, Orloff, John J
Publikováno v:
In Obstetrics & Gynecology 2003 101(4):711-721
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yael C. Cohen, Alexandra D. Carides, Kenneth Liu, Keaven M. Anderson, Daifotis Anastasia G, Norman Heyden, Peter H. Gann
Publikováno v:
JNCI Journal of the National Cancer Institute. 99:1366-1374
Background The Prostate Cancer Prevention Trial (PCPT) demonstrated a 24.8% reduction in the 7-year prevalence of prostate cancer among patients treated with finasteride (5 mg daily) compared with that among patients treated with placebo; however, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e28596e35e48117f436546cd7bfc449a
https://doi.org/10.1093/jnci/djm130
https://doi.org/10.1093/jnci/djm130
Autor:
D Ethgen, Jean-Yves Reginster, Daifotis Anastasia G, Philippe van der Auwera, G. Kreutz, Yannis Tsouderos, Bruno Flamion, Adolfo Diez-Perez, Pierre D. Delmas, Eric Abadie, Mary Smillie, Andrew Taylor, John Orloff, Bernard Avouac, Gonzalo Calvo, René Rizzoli, Andrea Laslop, Per Nilsson, Jean-Marc Kaufman, Willard H. Dere, Maria-Luisa Brandi, Bruce H. Mitlak, Fritz Lekkerkerker, Olof Johnell
Publikováno v:
Osteoporosis International. 17(1):1-7
Recent advances in the understanding of the epidemiology of osteoporosis suggest that certain parts of the current European guidelines for the registration of drugs in osteoporosis might be no longer substantiated. The object of this review is to pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9d2fc546f1dd9bc44bf78f21bd57048
https://doi.org/10.1007/s00198-005-1984-3
https://doi.org/10.1007/s00198-005-1984-3
Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates
Autor:
Kenneth C. Lasseter, Andrew Denker, Daifotis Anastasia G, Arturo G. Porras, Anu Santhanagopal
Publikováno v:
Clinical Drug Investigation. 25:107-114
Background and objective: Bisphosphonates are commonly used to treat and prevent osteoporosis. These compounds have unusual pharmacokinetic characteristics because they bind strongly to bone, and a portion becomes buried under newly formed bone. Once
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02ebcf1e7a3de6413460187ab300b1fd
https://doi.org/10.2165/00044011-200525020-00003
https://doi.org/10.2165/00044011-200525020-00003
Autor:
Kristel Vandormael, Thomas J. Schnitzer, Daifotis Anastasia G, Paul D. Miller, Eric S. Orwoll, Mark P. Ettinger, Clifford J. Rosen, Ronald Emkey
Publikováno v:
Clinical Drug Investigation. 24:333-341
To evaluate the efficacy and tolerability of alendronic acid 70mg once weekly for the treatment of male osteoporosis.This randomised, double-blind, placebo-controlled, 12-month trial compared the effect of alendronic acid 70mg once weekly or placebo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca1a923d193e18919601baf830e66b7
https://doi.org/10.2165/00044011-200424060-00003
https://doi.org/10.2165/00044011-200424060-00003
Autor:
Henry G. Bone, Tobias J. de Villiers, Nigel Gilchrist, Mei X. Wu, Daifotis Anastasia G, John J. Orloff, Arthur C. Santora, Marjorie M Luckey, Michael W Davie
Publikováno v:
Obstetrics & Gynecology. 101:711-721
To evaluate the efficacy and safety of alendronate 35 mg once weekly compared with alendronate 5 mg daily in the prevention of osteoporosis.We compared the efficacy and safety of treatment with alendronate 35 mg once weekly (n = 362) and alendronate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45c98f4ba7266d01fb63b56318ef563
https://doi.org/10.1016/s0029-7844(03)00008-5
https://doi.org/10.1016/s0029-7844(03)00008-5
Autor:
Thomas Musliner, Steven Winograd, Albert Leung, Frank L. Lanza, Hui Quan, James Torosis, Daifotis Anastasia G, Bruce Sahba, Robert Reyes, Howard Schwartz
Publikováno v:
The American Journal of Gastroenterology. 97:58-64
Alendronate (10 mg daily) has been shown in long term clinical trials to be an effective treatment for postmenopausal osteoporosis. A weekly dosing regimen of alendronate is preferred by both patients and physicians, as it has the potential to provid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3796cc4d35281a3f39f9f8c6cd128a
https://doi.org/10.1111/j.1572-0241.2002.05446.x
https://doi.org/10.1111/j.1572-0241.2002.05446.x